A unique European Public-Private Partnership to support drug development for cancer therapy

Role of Public-Private Partnerships in Addressing Non-Communicable Diseases in Low- and Middle-Income Countries

Stephane Mottola Fist SA

Who we are?

• FIST S.A., Paris

• FIST S.A. France Innovation Scientifique Transfert

• Private Technology Transfer Company created in 1992

• Subsidiary of CNRS, Centre National de Recherche Scientifique and OSEO

CNRS Key figures

• Founded in 1939, largest publicly funded research institute

• 17 Nobel laureates : Monod, Jacob, Lehn, Joliot-Curie

• Multidisciplinary (life sciences, physical and social science)

• 34 000 permanent employees

• 11 600 researchers

• 1260 research units

• Budget : $ 4,2 billion

• Life Science

• 326 research units

• Focus on Neurodegenerative/Psychiatric disorders, Oncology, Infectiousdiseases, Inflammatory, Autoimmune, Medicinal chemistry, Imaging

FIST S.A. Key figures

48 employees, 17 licensing officers, 6 lawyers

300 / 350 new patents each year

100 license and collaboration agreements signed per year

2 200 patent families

1300 licenses - $ 26 million Royalties in 2012

Blockbusters: Taxotere (Sanofi-Aventis), Navelbine (Pierre Fabre)

What is our challenge?

FIND THE PERFECT MATCH, BECAUSE….

…PHARMA AND BIOTECH ALWAYS COMPLAIN: YOUR TECHNOLOGY IS TOO EARLY-STAGE!

MATWIN: Maturation and Accelerating Translation With INdustry

• Partners :

o Pharma (AstraZeneca, AMGEN, BMS, Celgene, GSK, IPSEN, Merck-Serono, Novartis, ROCHE, SANOFI)

o Canceropoles (academics, clinicians)

o Institutions (Institut National du Cancer, Oseo)

• Associate Partners :

o TTOs: FIST S.A., INSERMT, S.A.T.T.

How to improve tech transfer : MATWIN

o Source & select research projects with high industrial value perspective

o Support theirmaturation up to the preclinical POC

P.P.P. model focused on oncology research

What are the P.P.P. assets?

• Mutualization of a sourcing platform to identify academic projects in Oncology

• Reduce risk on projects, with double early-stage scientific and industrialassessment

• Optimization of the industrial attractiveness of the project

• Reinforcement of project guidance (coaching, training)

• Provides access to world leading oncology companies (international Board)

o In 2011, 8 projects submitted 4 selected for Board audition, 1

funded by Roche (5 M$)

o In 2012, 14 projects submitted 8 selected for Board audition

(May 2013)

A case study : mAB against LG4/5 domain of Laminin

Before P.P.P.

• LG4/5 innovative target of the microenvironment

• LG4/5 specific of cancer cells, broadly expressed in cancer tissues

• In-vivo efficacy on colon and breast cancer

After P.P.P.

• LG4/5 interesting target but not validated

• Expression in various tissues too preliminary, need highernumber of cases

• In-vivo results not convincing

Suggestions : •Focus on rare cancers •Explore expression of target in metastasis•Explore Diagnostic

Refocused project with new development plan

A POTENTIAL DRUG CANDIDATE FOR COLON AND BREAST CANCERS

A POTENTIAL DRUG CANDIDATE FOR RARE, METASTATIC CANCERS OR DIAGNOSTIC

Thanks to MATWIN, FIST will be able to successfully transfer innovative

technologies to industry, providing new therapies for Cancer treatment.

The MATWIN PPP model could be adapted for use in LMCs to

address the increasing cancer burden.

www.matwin.org

Dr Stephane MottolaDirector of International Development

stephane.mottola@fist.fr

FIST S.A.

83 Bd Exelmans

• 75016 Paris – France

Tel: +33 (0)1 40 51 00 90

www.fist.fr